Hepatitis C and Kidney Transplantation

Overview

Journal Int J Nephrol

Publisher Wiley

Specialty Nephrology

Date 2011 Jul 15

PMID 21755059

Citations 4

Authors

Marco Carbone

Paul Cockwell

James Neuberger

Affiliations

Soon will be listed here.

Abstract

Hepatitis C virus (HCV) infection is relatively common among patients with end-stage kidney disease (ESKD) on dialysis and kidney transplant recipients. HCV infection in hemodialysis patients is associated with an increased mortality due to liver cirrhosis and hepatocellular carcinoma. The severity of hepatitis C-related liver disease in kidney transplant candidates may predict patient and graft survival after transplant. Liver biopsy remains the gold standard in the assessment of liver fibrosis in this setting. Kidney transplantation, not haemodialysis, seems to be the best treatment for HCV+ve patients with ESKD. Transplantation of kidneys from HCV+ve donors restricted to HCV+ve recipients is safe and associated with a reduction in the waiting time. Simultaneous kidney/liver transplantation (SKL) should be considered for kidney transplant candidates with HCV-related decompensated cirrhosis. Treatment of HCV is more complex in hemodialysis patients, whereas treatment of HCV recurrence in SLK recipients appears effective and safe.

Citing Articles

Hepatitis C virus infection in kidney transplantation-changing paradigms with novel agents.

Reddy Y, Nunes D, Chitalia V, Gordon C, Francis J Hemodial Int. 2018; 22 Suppl 1:S53-S60.

PMID: 29694721 PMC: 6815878. DOI: 10.1111/hdi.12659.

Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon.

Belga S, Doucette K World J Gastroenterol. 2016; 22(4):1650-63.

PMID: 26819530 PMC: 4721996. DOI: 10.3748/wjg.v22.i4.1650.

Hepatitis C infection in hemodialysis patients: A review.

Etik D, Ocal S, Boyacioglu A World J Hepatol. 2015; 7(6):885-95.

PMID: 25937865 PMC: 4411530. DOI: 10.4254/wjh.v7.i6.885.

Viral infection in renal transplant recipients.

Cukuranovic J, Ugrenovic S, Jovanovic I, Visnjic M, Stefanovic V ScientificWorldJournal. 2012; 2012:820621.

PMID: 22654630 PMC: 3357934. DOI: 10.1100/2012/820621.

References

Hooda A, Puri P, Narula A, Raychaudhury N, Varghese S, Basu A . Hepatitis C virus-related fibrosing cholestatic hepatitis in a renal transplant recipient. Indian J Gastroenterol. 2007; 25(6):308-9. View

Chan T, Wu P, Lok A, Lai C, Cheng I . Clinicopathological features of hepatitis C virus antibody negative fatal chronic hepatitis C after renal transplantation. Nephron. 1995; 71(2):213-7. DOI: 10.1159/000188715. View

Ozdemir B, Ozdemir F, Sezer S, Colak T, Haberal M . De novo glomerulonephritis in renal allografts with hepatitis C virus infection. Transplant Proc. 2006; 38(2):492-5. DOI: 10.1016/j.transproceed.2005.12.109. View

Feld J, Hoofnagle J . Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005; 436(7053):967-72. DOI: 10.1038/nature04082. View

Kliem V, van den Hoff U, Brunkhorst R, Tillmann H, Flik J, Manns M . The long-term course of hepatitis C after kidney transplantation. Transplantation. 1996; 62(10):1417-21. DOI: 10.1097/00007890-199611270-00007. View

Kahraman A, Witzke O, Scherag A, Putter C, Miller M, Dechene A . Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation. Clin Nephrol. 2010; 75(1):16-25. View

Mahmoud I, Sobh M, El-Habashi A, Sally S, El-Baz M, El-Sawy E . Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract. 2005; 100(4):c133-9. DOI: 10.1159/000085442. View

Fabrizi F, MARTIN P, Dixit V, Bunnapradist S, Dulai G . Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004; 20(11-12):1271-7. DOI: 10.1111/j.1365-2036.2004.02290.x. View

Abbott K, Lentine K, Bucci J, Agodoa L, Koff J, Holtzmuller K . Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol. 2004; 15(12):3166-74. DOI: 10.1097/01.ASN.0000145439.48387.BF. View

10.

Kasiske B, Cangro C, Hariharan S, Hricik D, Kerman R, Roth D . The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant. 2002; 1 Suppl 2:3-95. View

11.

Sikole A, Dzekova P, Selja N, Gaseva M, Nikolov I, Zabzun M . Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy. Ren Fail. 2007; 29(8):961-6. DOI: 10.1080/08860220701641579. View

12.

Northup P, Argo C, Nguyen D, McBride M, Kumer S, Schmitt T . Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010; 23(10):1038-44. DOI: 10.1111/j.1432-2277.2010.01092.x. View

13.

Pereira B, Wright T, Schmid C, Bryan C, Cheung R, Cooper E . Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study. Kidney Int. 1994; 46(3):886-92. DOI: 10.1038/ki.1994.346. View

14.

van Leusen R, Adang R, de Vries R, Cnossen T, Konings C, Schalm S . Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2007; 23(2):721-5. DOI: 10.1093/ndt/gfm724. View

15.

Schmitz V, Kiessling A, Bahra M, Puhl G, Kahl A, Berg T . Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann Transplant. 2008; 12(3):22-7. View

16.

Rostaing L, RUMEAU J, Cisterne J, Izopet J, Chabannier M, Durand D . Liver histology in renal transplant patients after more than 10 years of hepatitis C virus infection. Transplant Proc. 1996; 28(5):2836-7. View

17.

. The current state of chronic dialysis treatment in Japan (as of December 31, 2000). Ther Apher Dial. 2003; 7(1):3-35. View

18.

Durlik M, Gaciong Z, Rowinska D, Rancewicz Z, Lewandowska D, Kozlowska B . Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int. 1998; 11 Suppl 1:S135-9. DOI: 10.1007/s001470050445. View

19.

Eason J, Gonwa T, Davis C, Sung R, Gerber D, Bloom R . Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant. 2008; 8(11):2243-51. DOI: 10.1111/j.1600-6143.2008.02416.x. View

20.

Fabrizi F, MARTIN P, Ponticelli C . Hepatitis C virus infection and renal transplantation. Am J Kidney Dis. 2001; 38(5):919-34. DOI: 10.1053/ajkd.2001.28576. View